CD19, BCMA · relapsed/refractory multiple myeloma Phase I clinical trial

According to official protocol filings (target population synthesized by CMDN from study details, not an official registry field), this study is primarily designed for patients with [Relapsed/refractory]. Eligibility requires verified clinical confirmation by investigators regarding prior lines of therapy, active disease biomarkers, and performance status.

According to verified protocol filings, key eligibility thresholds include: age 18–75 years, ECOG performance status ≤ 2, ≥ 3 prior lines of therapy. The study specifies 10 inclusion and 22 exclusion criteria covering detailed organ function and medical history. Final enrollment confirmation is determined by investigators at participating hospital trial centers.

The core therapeutic target or investigational mechanism is [CD19, BCMA]. It aims to selectively eradicate clonal plasma cells or redirect anti-tumor immune responses, representing an active area of precision hematology research.

This study is registered as a [Phase I] clinical trial. The protocol is conducted under rigorous ethical and Good Clinical Practice (GCP) oversight approved by institutional ethics committees.

This is an international multi-centre study with 0 study centres in China and 1 overseas centres. The lead institution is [Chinese PLA General Hospital (301 Hospital)]. Prominent sites include Chinese PLA General Hospital (301 Hospital). Eligible domestic patients can seek screening at the nearest participating centre.

The official public registration identifier for this protocol is [NCT07620314] (CLINICALTRIALS_GOV). Patients and researchers can verify registration details and authorizations on ClinicalTrials.gov.